

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Post-Effective Amendment No. 1**  
**to**  
**FORM S-3**  
**REGISTRATION STATEMENT**  
*Under*  
*The Securities Act of 1933*

---

**NANTHEALTH, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**27-3019889**  
(I.R.S. Employer  
Identification Number)

**760 W Fire Tower Rd, Suite 107**  
**Winterville, North Carolina 28590**  
**(855) 949-6268**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Rao Haris Naseem, M.D.**  
**Chief Executive Officer**  
**NantHealth, Inc.**

**760 W Fire Tower Rd, Suite 107**  
**Winterville, North Carolina 28590**  
**(855) 949-6268**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**Martin J. Waters**  
**Thomas E. Hornish**  
**Savir S. Punia**  
**Wilson Sonsini Goodrich & Rosati**  
**Professional Corporation**  
**12235 El Camino Real**  
**San Diego, CA 92130**  
**(858) 350-2300**

**Bob Petrou**  
**Chief Financial Officer**  
**NantHealth, Inc.**  
**760 W Fire Tower Rd, Suite 107**  
**Winterville, North Carolina 28590**  
**(855) 949-6268**

---

**APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:** Not applicable. Removal from registration of all securities that were not sold pursuant to the above referenced registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and

list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.

If this form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act.

---

---

---

**EXPLANATORY NOTE  
DEREGISTRATION OF SECURITIES**

This Post-Effective Amendment No. 1 is being filed by NantHealth, Inc., a Delaware corporation (the “**Registrant**”), to withdraw and remove from registration all of the unsold securities under the Registration Statement on [Form S-3](#) (Registration No. 333-254937) (the “**Registration Statement**”), which was filed with the U.S. Securities and Exchange Commission on March 31, 2021, and became effective on May 6, 2021, pertaining to the registration of up to \$200,000,000 in the aggregate of securities.

The Registrant is terminating all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any and all securities registered under the Registration Statement that remain unsold, the Registrant hereby removes from registration any and all securities registered but unsold under the Registration Statement as of the date hereof, if any. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Winterville, North Carolina, on January 25, 2024.

**NANTHEALTH, INC.**

By: /s/ Rao Haris Naseem, M.D.  
Rao Haris Naseem, M.D.  
President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
<u>/s/ Rao Haris Naseem, M.D.</u> Rao Haris Naseem, M.D.	President, Chief Executive Officer, and Director <i>(Principal Executive Officer)</i>	January 25, 2024
<u>/s/ Bob Petrou</u> Bob Petrou	Chief Financial Officer <i>(Principal Financial and Accounting Officer)</i>	January 25, 2024
* <u>Patrick Soon-Shiong, M.D.</u>	Chairman of the Board	January 25, 2024
* <u>Kirk K. Calhoun</u>	Director	January 25, 2024
* <u>Michael Blaszyk</u>	Director	January 25, 2024

\*By:

/s/ Bob Petrou  
Bob Petrou  
*Attorney-in-Fact January 25, 2024*